Regenerative Medical Solutions
Revolutionary Therapeutic For Type 1, Type 2 and Type 3C Diabetes
MCC invested in RMS to advance treatments for all types of diabetes, starting with Type 3c. Less common than Type 1 or Type 2 diabetes, Type 3c diabetes, also referred to as “pancreatogenic” diabetes, results from a pancreatic condition such as chronic pancreatitis, cystic fibrosis, pancreatic cancer or a total pancreatectomy.
Like Type 1 diabetes, Type 3c is treated with insulin injections but can be more difficult to manage. it is a complex condition that has not been widely researched or understood by many medical professionals. However, RMS recognized that Type 3c has several advantages for developing and testing their innovative new diabetes treatments.
MCC’s investment supports the continued development of RMS’s patented technology and novel approach to develop a revolutionary protocol to grow healthy and resilient pancreatic cells to improve the lives of people with all types of diabetes.
RMS is a privately held biotechnology company utilizing human induced pluripotent (nonembryonic) stem cell derived islet-like clusters with therapeutic applications in pancreatitis, type 1 and type 2 diabetes. This revolutionary technology is built on over 25 years of research by Dr. Jon Odorico, MD, FACS at the University of Wisconsin-Madison and subsequently at RMS. RMS was founded by Anthony Kolton and Dr. Jon Odorico, MD, FACS to develop an ethical cell therapy resulting in a cure for diabetes.